Acadia Pharmaceuticals reports Q3 results, raises DAYBUE guidance and outlines 2028 sales target
Acadia Pharmaceuticals posted Q3 2026 revenue of $342 million, with DAYBUE sales of $140 million and NUPLAZID sales of $202 million, the latter up 12% on an adjusted basis. The company extended DAYBUE’s U.S. patent protection to March 2041 and lifted its 2026 DAYBUE sales outlook to $505 million‑$520 million, adding a $700 million target for 2028. It also narrowed full‑year NUPLAZID guidance to $760 million‑$775 million and forecast total 2026 revenue of $1.265 billion‑$1.295 billion.
Why it matters
The raised DAYBUE guidance and new 2028 sales target increase the company’s projected revenue stream, which could affect investor valuation models. The narrowed NUPLAZID outlook and total‑year revenue range provide a clearer earnings forecast for the remainder of 2026.
Key facts
- 1Q3 2026 revenue was $342 million. seekingalpha.com
- 2DAYBUE net sales in the quarter were $140 million. seekingalpha.com
- 3NUPLAZID net sales reached $202 million, up 12% on an adjusted basis. finance.yahoo.com
- 4DAYBUE U.S. patent protection was extended to March 2041. finance.yahoo.com
- 5DAYBUE 2026 sales guidance was raised to $505 million‑$520 million. seekingalpha.com
- 6Acadia set a DAYBUE sales target of $700 million for 2028. seekingalpha.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.